James Gordon CFA
Stock Analyst at Barclays
(3.10)
# 2,508
Out of 4,408 analysts
119
Total ratings
56.8%
Success rate
5.2%
Average return
Main Sectors:
Stocks Rated by James Gordon CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,500p | $13,462.00 | +22.57% | 12 | Jun 10, 2026 | |
| LON: GSK GSK plc | Maintained: Sell | 1,800p | $1,984.00 | -9.27% | 17 | Jun 9, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 120.00 | $122.08 | -1.70% | 7 | Jun 8, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €900.00 | $786.30 | +14.46% | 12 | May 28, 2026 | |
| SWX: ROP Roche Holding AG | Maintained: Buy | CHF 410.00 | $330.00 | +24.24% | 13 | May 26, 2026 | |
| SWX: GALD Galderma Group AG | Maintained: Buy | CHF 200.00 | $172.15 | +16.18% | 21 | May 26, 2026 | |
| LON: 0MGB Genmab A/S | Rated: Buy | kr 2,500 | $1,617.64 | +54.55% | 6 | May 22, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 300.00 | $283.55 | +5.80% | 16 | May 19, 2026 | |
| SWX: SDZ Sandoz Group AG | Upgraded: Buy | CHF 75.00 | $67.04 | +11.87% | 6 | May 5, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €85.00 | $76.59 | +10.98% | 6 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | 1,350p | $1,480.00 | -8.78% | 2 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €22.00 | $24.94 | n/a | 1 | Jan 23, 2025 |
AstraZeneca PLC
Jun 10, 2026
Maintained: Buy
Price Target: 16,500p
Current: $13,462.00
Upside: +22.57%
GSK plc
Jun 9, 2026
Maintained: Sell
Price Target: 1,800p
Current: $1,984.00
Upside: -9.27%
Novartis AG
Jun 8, 2026
Reiterated: Hold
Price Target: CHF 120.00
Current: $122.08
Upside: -1.70%
argenx SE
May 28, 2026
Maintained: Buy
Price Target: €900.00
Current: $786.30
Upside: +14.46%
Roche Holding AG
May 26, 2026
Maintained: Buy
Price Target: CHF 410.00
Current: $330.00
Upside: +24.24%
Galderma Group AG
May 26, 2026
Maintained: Buy
Price Target: CHF 200.00
Current: $172.15
Upside: +16.18%
Genmab A/S
May 22, 2026
Rated: Buy
Price Target: kr 2,500
Current: $1,617.64
Upside: +54.55%
Novo Nordisk A/S
May 19, 2026
Maintained: Hold
Price Target: kr 300.00
Current: $283.55
Upside: +5.80%
Sandoz Group AG
May 5, 2026
Upgraded: Buy
Price Target: CHF 75.00
Current: $67.04
Upside: +11.87%
Sanofi
Apr 23, 2026
Maintained: Hold
Price Target: €85.00
Current: $76.59
Upside: +10.98%
Mar 2, 2026
Maintained: Sell
Price Target: 1,350p
Current: $1,480.00
Upside: -8.78%
Jan 23, 2025
Downgraded: Sell
Price Target: €22.00
Current: $24.94
Upside: n/a